Survival in 222 adult patients with acute leukaemia treated with intermittent combination chemotherapy programme

Publisher Website
Google Scholar
Abstract
222 patients aged 15–59 years with acute leukaemia were treated with intermittent combination chemotherapy consisting of six 5‐day courses of cytotoxic drugs as induction treatment followed by 3 years of maintenance therapy in patients who obtained complete remission (CR). CR was achieved in 50.3% of 161 patients (early deaths included) with acute myelogenous leukaemia (AML). The observed cumulative 5‐yr survival rate (observation time 1–12.25 yr) calculated by the life table method was 12% in AML. Among patients who obtained CR, those aged 40–59 yr appeared to fare better than younger patients (5‐yr survival: 24%). The M‐3 subtype was an adverse prognostic factor. In acute lymphoblastic leukaemia (ALL) the CR rate was 83.6% and the observed cumulative 5‐yr survival rate was 14%. Women fared better than men.